KMT5A and carcinoma: In addition, compound 8 wastested in human liverhepatocellular carcinoma (HepG2) cells, which was previously observedto be insensitive to KMT9 knockdown or inhibition., CETSAassays using HepG2 cells showed a strongly increased ΔTm for KMT9 upon treatment with compound 8 compared to the DMSO control (ΔTm = 8 K), whereas no ΔTm wasobserved for KMT5A (ΔTm = 0.1 K),which indicated that prodrug compound 8 can target endogenousKMT9 after releasing the ethyl group by the esterase in HepG2 cells(Figure S5D–G).